Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lumos Diagnostics Holdings (LDX) Fair Value & Analysis

Healthcare · AU · Market cap A$97.0M

PriceA$0.1150
Fair ValueA$0.0300
Upside-73.9%
Quality92/100
Evidence: Low Range A$0.0200 – A$0.0400

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Lumos Diagnostics Holdings (LDX) currently trades at A$0.1150, while our model-based Fair Value estimate is A$0.0300 — implying the stock looks roughly 73.9% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Lumos Diagnostics Holdings (LDX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$0.0300 versus a price of A$0.1150 — about −74% (overvalued). Model-based estimate, not financial advice.
What is the fair value of LDX?
Our 21-model fair value for Lumos Diagnostics Holdings is A$0.0300 (as of Jun 24, 2026), built from audited fundamentals. The current price is A$0.1150.
What is the quality score of LDX?
Lumos Diagnostics Holdings has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.